ArticleMolecular medicine reports2017
miR-590 regulates WT1 during proliferation of G401 cells.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- MiR-194-5p inhibited metastasis and EMT of nephroblastoma cells through targeting Crk.The Kaohsiung journal of medical sciences · 2020Article
- MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.American journal of cancer research · 2020Article
- Article
- miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephroblastoma (Wilms' tumor) is frequently associated with mortality in children. MicroRNAs (miRNAs) are important for tumor development serving as oncogenes or tumor suppressors. In the present study, miRNA‑590 (miR‑590) was identified to be upregulated in Wilms' tumor tissues compared with the normal adjacent tissues. Additionally, the levels of miR‑590 were consistent with their clinical stage. Wilms' tumor 1 (WT1) was considered to be a tumor suppressor in certain tumor types, and it has been detected at low expression levels in various types of cancer with high cell proliferation and aggressive behavior. The expression levels of miR‑590 were quantified using reverse transcription‑quantitative polymerase chain reaction. Cell proliferation was measured using 5‑ethynyl‑20‑deoxyuridine assays. The protein expression levels of WT1 were investigated by western blot analysis. To the best of our knowledge, the present study was the first to determine that WT1 was a target gene of miR‑590 as miR‑590 was able to negatively regulate WT1 expression level by binding to the specific target site within the 3'‑untranslated region (3'‑UTR) of WT1 in G401 cells. Additionally, overexpression of miR‑590 promoted G401 cell proliferation which was consistent with the effect of small interfering RNA‑WT1. Subsequently, the present study determined that the cell phenotype altered by miR‑590 overexpression may be reversed by upregulation of WT1 in G401 cells. In conclusion, the observations indicated that miR‑590 may function as an oncogene via targeting WT1 to induce G401 cell proliferation. These results may contribute to current understanding of the function of miR‑590 in nephroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.